BioCentury
ARTICLE | Company News

Lubris, Novartis deal

April 14, 2017 7:41 PM UTC

Novartis exercised an option for exclusive, ex-European rights to ECF843 recombinant human lubricin from Lubris for ophthalmic indications. The candidate has completed a Phase II trial in dry eye. The partners declined to disclose financial terms. ...

BCIQ Company Profiles

Lubris LLC

Novartis AG

BCIQ Target Profiles

Proteoglycan 4 (PRG4) (HAPO)